# BEAM — baseline

## Metadata

ticker: BEAM
arm: baseline
judge_prompt_version: v2
context_sha256: 7d9fdd8284e254b73b98e05bd836568488e1491ca405d0b2bff500e28309e188
llm_calls: 7
llm_endpoints: anthropic
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 368, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.172, "latency_s_total": 4.172, "parse_failure": 0, "prompt_tokens": 3212, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 339, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.895, "latency_s_total": 3.895, "parse_failure": 0, "prompt_tokens": 2427, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 183, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.282, "latency_s_total": 2.282, "parse_failure": 0, "prompt_tokens": 688, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 176, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.329, "latency_s_total": 2.329, "parse_failure": 0, "prompt_tokens": 681, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 236, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.468, "latency_s_total": 2.468, "parse_failure": 0, "prompt_tokens": 412, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 184, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 1.748, "latency_s_total": 1.748, "parse_failure": 0, "prompt_tokens": 449, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1278, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 17.556, "latency_s_total": 17.556, "parse_failure": 0, "prompt_tokens": 1962, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 25.67,
  "currency": "USD",
  "market_cap": 2651394304.0,
  "forward_pe": -5.414047,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from the Latest SEC Filings

## Financial Position and Losses
The company has accumulated significant operating losses since inception, with a net loss of $80.0 million in 2025, $376.7 million in 2024, and $132.5 million in 2023. As of December 31, 2025, the accumulated deficit reached $1.6 billion. However, the company maintains $1.2 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.

## Capital Requirements and Funding Challenges
Substantial additional funding will be needed to support ongoing research and development, clinical trials, and potential commercialization efforts. The company has no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners. If unable to raise capital on acceptable terms, the company may be forced to delay, reduce, or eliminate research programs and commercialization efforts.

## Strategic Restructuring
In October 2023, the company announced a portfolio reprioritization and strategic restructuring that included cost-reduction initiatives, resulting in the pausing or elimination of certain pipeline programs.

## Early-Stage Development Status
The company is an early-stage biotech firm founded in January 2017 that has not yet completed any pivotal clinical trials or obtained marketing approvals for any product candidates. Development timelines typically span 10-15 years from discovery to commercialization.

## Profitability Outlook
The company expects to continue incurring significant losses for the foreseeable future and may never achieve profitability, as it has not yet generated meaningful product revenues.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the main categories being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has incurred significant operating losses since inception, with an accumulated deficit of $1.6 billion as of December 31, 2025, and net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023 respectively.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability.
- **Need for additional capital**: Substantial additional funding will be required to continue operations, expand clinical trials, and seek marketing approvals. Without adequate capital, the company may be forced to delay, reduce, or eliminate research and development programs.

## Product Development and Commercialization Challenges
- **No completed pivotal trials**: The company has not completed any pivotal clinical trials and has no product candidates approved for commercialization.
- **Long development timeline**: Developing new medicines typically takes 10 to 15 years from discovery to patient availability.
- **Limited operating history**: As an early-stage company in a rapidly evolving field, the company has limited track record in successfully completing clinical trials, obtaining marketing approvals, manufacturing at commercial scale, or conducting commercialization activities.
- **Uncertain success**: Even if product candidates are successfully developed and approved, commercial success is not guaranteed.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics is trading at $25.67 with a market capitalization of $2.65 billion, positioned in the mid-range of its 52-week trading band ($20.23–$38.26). The company generated $156.0 million in revenue but reported a net loss of $86.5 million, reflecting a concerning -55.45% profit margin typical of early-stage biotech firms investing heavily in R&D and clinical development. The negative forward P/E ratio underscores the company's current unprofitability, and the absence of dividend yield indicates capital is being reinvested into operations rather than returned to shareholders. While revenue generation demonstrates commercial traction, the substantial operating losses and negative margins highlight the critical need for pipeline advancement and eventual profitability to justify current valuation levels.

### Recent Developments

No recent news items are currently available for Beam Therapeutics. Investors should monitor the company's SEC filings, including its most recent 10-Q filing (August 4, 2026) and 10-K filing (February 24, 2026), which highlight significant risk factors affecting the business. With a negative profit margin of -55.45% and net losses of $86.5 million against $156 million in revenue, the company remains in a pre-profitability phase typical of early-stage biotech firms. The stock's 33% decline from its 52-week high of $38.26 to the current price of $25.67 reflects investor concerns about execution and cash burn, making pipeline progress and clinical trial results critical catalysts to watch.

### SEC Filing Highlights

Beam Therapeutics reported a net loss of $80.0 million in 2025 with an accumulated deficit of $1.6 billion, though the company maintains $1.2 billion in cash and equivalents expected to fund operations for at least 12 months. The company faces substantial capital requirements for ongoing R&D and clinical trials, with no committed funding sources beyond its credit facility with Sixth Street Lending Partners. As an early-stage biotech firm founded in 2017 with no completed pivotal trials or marketing approvals, Beam expects to continue incurring significant losses for the foreseeable future and may never achieve profitability without meaningful product revenues. The company's October 2023 strategic restructuring included cost-reduction initiatives and the pausing or elimination of certain pipeline programs to extend runway.

### Risk Factors

- **Substantial capital requirements and path to profitability uncertain**: Beam has accumulated losses of $1.6 billion as of December 31, 2025, with net losses of $80.0 million in 2025 alone. The company expects continued losses for the foreseeable future and may never achieve profitability, requiring significant additional funding to advance clinical programs and potentially forcing delays or elimination of R&D initiatives if capital becomes constrained.

- **No approved products and extended development timelines**: Beam has no completed pivotal trials or approved product candidates. Gene editing therapies typically require 10-15 years from discovery to commercialization, and as an early-stage company with limited operating history, the company faces substantial execution risk in successfully completing trials, obtaining regulatory approvals, and scaling manufacturing.

- **Uncertain commercial viability**: Even if product candidates are successfully developed and approved, commercial success is not guaranteed. The company has no track record in commercializing gene editing therapies, and market adoption, reimbursement, and competitive dynamics remain uncertain.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics is an early-stage gene editing company founded in 2017 that has generated $156.0 million in revenue while carrying a $2.65 billion market capitalization, yet remains deeply unprofitable with a net loss of $86.5 million and an accumulated deficit of $1.6 billion — a profile characteristic of a company still years away from commercial-stage operations. The stock is notable now because it has declined 33% from its 52-week high of $38.26 to $25.67, reflecting investor unease over cash burn and execution risk, even as the company's $1.2 billion cash position provides a meaningful but finite operational runway. The single most important near-term variable is clinical trial progress: meaningful positive data from pipeline programs would be the primary catalyst capable of rebuilding investor confidence and justifying the current valuation, while further setbacks or program eliminations would intensify concerns about the company's long-term viability.

### Outlook
The directional lean on Beam Therapeutics is **cautious**, with the potential to become more constructive if specific conditions are met. On the tailwind side, the company's $1.2 billion cash position provides a meaningful buffer that reduces near-term financing risk, and the broader gene editing field continues to attract scientific and investor interest as a potentially transformative therapeutic modality. However, headwinds are significant: the company has no approved products, carries an accumulated deficit of $1.6 billion, has already undergone a strategic restructuring that paused or eliminated pipeline programs, and faces a competitive landscape where market adoption and reimbursement dynamics remain deeply uncertain. Investors should monitor several key variables — most critically, the quality and timing of clinical trial data from remaining pipeline programs, the pace of cash consumption relative to the stated runway, and whether the company can secure additional committed funding sources beyond its existing credit facility. Any positive pivotal-stage clinical readouts or regulatory milestones would be the clearest signal to shift toward a more constructive view; conversely, further program eliminations, deteriorating cash runway, or clinical setbacks would deepen concerns and reinforce the cautious stance.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "founded in 2017"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "an early-stage biotech firm founded in January 2017."

---

CLAIM: "generated $156.0 million in revenue"
LABEL: SUPPORTED
REASON: The raw source data shows revenue of $156,035,008, which rounds to $156.0 million.

---

CLAIM: "$2.65 billion market capitalization"
LABEL: SUPPORTED
REASON: The raw source data shows market_cap of $2,651,394,304, which rounds to $2.65 billion.

---

CLAIM: "net loss of $86.5 million"
LABEL: UNSUPPORTED
REASON: The raw source data shows net_income of -$86,520,000 (rounds to $86.5 million), but the SEC filing highlights and Risk Factors sections consistently state the 2025 net loss was $80.0 million; the $86.5 million figure conflicts with the SEC-sourced figure of $80.0 million and no reconciliation is provided in the source data.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and Risk Factors sections explicitly state "accumulated deficit reached $1.6 billion as of December 31, 2025."

---

CLAIM: "declined 33% from its 52-week high of $38.26 to $25.67"
LABEL: SUPPORTED
REASON: Computed decline: (38.26 − 25.67) / 38.26 = 12.59 / 38.26 ≈ 32.9%, which rounds to 33%; both $38.26 (52-week high) and $25.67 (current price) are present in the raw source data.

---

CLAIM: "$1.2 billion cash position"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "the company maintains $1.2 billion in cash, cash equivalents, and marketable securities."

---

---

**OUTLOOK**

---

CLAIM: "$1.2 billion cash position provides a meaningful buffer that reduces near-term financing risk"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state the company maintains $1.2 billion in cash, cash equivalents, and marketable securities, expected to fund operations for at least the next 12 months.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: Explicitly stated in both RAG SEC Highlights and Risk Factors as of December 31, 2025.

---

CLAIM: "has already undergone a strategic restructuring that paused or eliminated pipeline programs"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "In October 2023, the company announced a portfolio reprioritization and strategic restructuring…resulting in the pausing or elimination of certain pipeline programs."

---

CLAIM: "beyond its existing credit facility" (implying the credit facility with Sixth Street Lending Partners is the only committed funding source)
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both state "no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners."

---

**Summary of findings:** The most material discrepancy is the net loss figure. The Executive Summary cites $86.5 million (derived from the raw stock data field), while the SEC filing highlights — the more authoritative source for the annual net loss — consistently report $80.0 million for 2025. This inconsistency is present in the pre-written sections as well and propagates into the Executive Summary without reconciliation, rendering that specific claim UNSUPPORTED against the SEC-sourced figures.
